^
Association details:
Biomarker:KMT2D mutation
Cancer:Follicular Lymphoma
Regimen: (cyclophosphamide + doxorubicin hydrochloride + prednisone + Rituxan (rituximab) + vincristine)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Source:
Title:

MUTATIONAL PROFILE IN NEWLY DIAGNOSED FOLLICULAR LYMPHOMA AND CORRELATION WITH OUTCOME AFTER TREATMENT WITH INMUNOCHEMOTHERAPY

Published date:
06/12/2020
Excerpt:
Among genes frequently mutated, we observed an association with worse PFS in cases bearing mutations in KMT2D, BCL7A and ARID1B…Despite being infrequent, PLCG2 and TNFA1P3 mutated cases showed a statistically significant dismal outcome…